Back

Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial

21 May 2022 (11:40 - 11:55)
Organised by:
Congress Presentation Part of: Young Investigator Award: clinical research Pharmacotherapy HFA Premium Access Heart Failure 2022

About the speaker

Photo
Doctor Jawad Haider Butt

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

3 More presentations in this session

Presentation thumbnail
Discontinuation of guideline-recommended heart failure treatments after a first hospitalization for heart failure - An analysis from the SwedeHF registry
Abstract Slides
Presentation thumbnail
Distinct pathophysiological pathways in women and men with heart failure
Doctor A. Ravera (Brescia, IT)
Abstract Slides Video
Presentation thumbnail
The effect of dapagliflozin according to iron status and its effect on iron metabolism: insights from DAPA-HF
Doctor K. Docherty (Glasgow, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award: clinical research
Video

The Event

Event poster

Heart Failure 2022

21 May 2022 11:40 CET
You may be interested in
thumbnail
Congress Session
Frailty in heart failure
21 May 2023
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
31 August 2024
thumbnail
Congress Presentation
Efficacy and safety of sacubitril/valsartan according to frailty in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial
29 August 2022
thumbnail
Congress Presentation
Implantable cardioverter-defibrillator at least as effective in frail patients with nonischemic heart failure with reduced ejection fraction: extended follow-up of the DANISH trial
17 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources